How Difficult Are Diagnostic And Screening Tests For Patients?

Published Sep 25, 2013
Boston, MA, USA - Medical tests with greater morbidity are less likely to be completed by patients, and this lack of health maintenance adherence has implications for future health outcomes. Knowing how medical tests may differ in their temporary changes to a patient’s quality of life can help doctors, clinicians and institutions better understand the patient experience and improve upon it. Such knowledge also gives patients actual data about medical testing rather than hearsay. Researchers at Massachusetts General Hospital have been working on making such information available. In the article, “Responsiveness of the Testing Morbidities Index in Colonoscopy,” published in Value in Health, a new survey instrument called the Testing Morbidities Index (TMI) was used in patients undergoing screening colonoscopy. The study focused on responsiveness - thus the sensitivity of the TMI to detect change in quality of life caused by the testing experience.  The authors found that the TMI, a brief 7 question survey, was much more responsive to change than two standard instruments, the EQ-5D-5L and the SF-6D; they showed no responsiveness or minimal responsiveness, respectively. The TMI survey asks patients about emotional and physical discomforts that occur before, during and after a testing procedure. The results showed that essentially all of the morbidity of colonoscopy occurs before the actual procedure. Patients can have substantial anxiety before colonoscopy and the bowel preparation is very uncomfortable for some. Morbidity during and after the procedure, however, is relatively minimal. "Our results are not a surprise to clinicians and experienced patients, but they would likely be of interest to inexperienced patients who are scared to have the test," said the lead author on the study, Dr. J. Shannon Swan, MD, an Associate Professor at Harvard Medical School and a Senior Scientist at the MGH Institute for Technology Assessment. He adds, "More importantly, the TMI allows us to compare tests to one another. When we developed the TMI, we first tested it in breast biopsy, which we find has a different morbidity profile than colonoscopy." Lastly, Dr. Swan notes that for the future, the TMI results can be presented in various ways: "We can look at the morbidity in individual survey items, and can also combine the items so they can be used for various purposes. We are now implementing a TMI version that can provide results applicable to cost-effectiveness analysis."

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×